Henlius is the leading biosimilar drug companies in China. The Company was jointly established in 2009 by Fosun Pharmaceutical and a team of scientists led by Dr. Scott Liu and Dr. Jiang Weidong. The Company is committed to the development and commercialization of monoclonal antibody (mAbs) biosimilar drugs, bio-betters and novel mAbs drugs. Since its establishment, the Company has always stayed true to its core value of "Quality, Speed, Innovation", and has established an advanced platform of antibody drug R&D and industrialization, which has launched a variety of pipeline drugs. Currently, the Company has comprehensive product lines, and has completed the declaration of 11 products for 17 indications of IND, and obtained 13 clinical approval documents in total. Its key product, the rituximab biosimilar drug is expected to be launched in 2018, filing the current supply gap.